Shorter hormone therapy as effective as longer course for prostate cancer

09/25/2013 | U.S. News & World Report

Short-term hormone therapy after radiation treatment had a comparable effect on overall survival and disease-specific survival as longer-course therapy in men with intermediate-risk prostate cancer, according to a study presented at a meeting of the American Society for Radiation Oncology. In the study of 133 patients, disease-specific survival was 96% for both short- and long-term hormone therapy groups while 10-year overall survival was 61% in the shorter-course group and 65% in the long-term group.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA